Results 291 to 300 of about 47,200 (309)
Some of the next articles are maybe not open access.
Dabigatran in Clinical Practice
Clinical Therapeutics, 2012Stroke and systemic thromboembolism remain critical causes of mortality and morbidity in patients with paroxysmal or persistent atrial fibrillation. Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation. Randomized clinical data demonstrate dabigatran to be
Christopher R. Ellis +1 more
openaire +3 more sources
American Journal of Health-System Pharmacy, 2011
As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States.
Steven R. Kayser +3 more
openaire +2 more sources
As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States.
Steven R. Kayser +3 more
openaire +2 more sources
Dabigatran-Induced Esophagitis
Clinical Gastroenterology and Hepatology, 2014We report 2 cases of drug-induced esophagitis associated with dabigatran, a new oral anticoagulant. Both patients were prescribed dabigatran at 110 mg twice daily for atrial fibrillation as an alternative to warfarin. The first case was a 70-year-old man who had been taking dabigatran for 14 days and was referred to our hospital because of retrosternal
Yoshihiro Hayashi +2 more
openaire +3 more sources
The Antithrombotic Effect of Dabigatran
Canadian Journal of Cardiology, 2014A 72-year-old man presented to the emergency department because of a sudden onset of left-sidedweakness. The patient had his first cerebral vascular accident at the age of 49 years. Atrial fibrillation (AF) and hypertension were diagnosed at that time.
Hsueh Han Wang +2 more
openaire +3 more sources
Drug Research, 2019
Abstract Purpose Due to bioanalytical limitations it was previously not possible to evaluate the pharmacokinetics of dabigatran etexilate. We have developed validated methods to assay dabigatran etexilate, unconjugated dabigatran, and total dabigatran that will allow for a complete investigation into the pharmacokinetics of dabigatran etexilate ...
Zia Tayab, Mohammed Bouhajib
openaire +3 more sources
Abstract Purpose Due to bioanalytical limitations it was previously not possible to evaluate the pharmacokinetics of dabigatran etexilate. We have developed validated methods to assay dabigatran etexilate, unconjugated dabigatran, and total dabigatran that will allow for a complete investigation into the pharmacokinetics of dabigatran etexilate ...
Zia Tayab, Mohammed Bouhajib
openaire +3 more sources
Effect of Bisoprolol on the Level of Dabigatran
American Journal of Therapeutics, 2020Background: Many patients receiving dabigatran treatment might also require bisoprolol therapy. However, there is a possibility that bisoprolol as significant P-glycoprotein inhibitor might interact with dabigatran. Study Question: To investigate the impact of concomitant bisoprolol
Frantisek Nehaj +4 more
openaire +2 more sources
2017
With the limited availability of reversal agents, it may be difficult to treat a patient who has overdosed on a direct oral anticoagulant (DOAC). Treatment of these patients may be guided by time elapsed since ingestion, laboratory values, and overall clinical stability.
openaire +2 more sources
With the limited availability of reversal agents, it may be difficult to treat a patient who has overdosed on a direct oral anticoagulant (DOAC). Treatment of these patients may be guided by time elapsed since ingestion, laboratory values, and overall clinical stability.
openaire +2 more sources
Total Synthesis of Dabigatran Revisited; Synthesis of Amidine‐Tosylated Dabigatran
ChemistrySelect, 2019AbstractThe total synthesis of a new dabigatran derivative featuring a tosyl protecting group at the amidine group of dabigatran was explored. During the course of this work, different new synthetic pathways towards dabigatran intermediates are investigated and known concepts revisited.
Stefan Jopp +6 more
openaire +2 more sources
Journal of Medicinal Chemistry, 2012
Recent studies have revealed that compounds believed to be highly selective frequently address multiple target proteins. We investigated the protein interaction profile of the widely prescribed thrombin inhibitor dabigatran (1), resulting in the identification and subsequent characterization of an additional target enzyme.
Mathias Dreger +11 more
openaire +2 more sources
Recent studies have revealed that compounds believed to be highly selective frequently address multiple target proteins. We investigated the protein interaction profile of the widely prescribed thrombin inhibitor dabigatran (1), resulting in the identification and subsequent characterization of an additional target enzyme.
Mathias Dreger +11 more
openaire +2 more sources
Bloedingsrisico’s van dabigatran
Huisarts en wetenschap, 2015Dabigatran beschermt beter tegen CVA’s dan warfarine bij patienten met non-valvulair atriumfibrilleren. Over de veiligheid van het middel zijn de berichten minder positief. Zo wordt dabigatran steeds vaker in verband gebracht met een verhoogde kans op ernstige bloedingen.
openaire +2 more sources